NuPathe (PATH) to Cut Workforce 50%, Delay IND for NP202, Cut NP101 Spending
- Top 10 News for 8/24 - 8/28: Markets Volatile on Continued China Worries; Revised Q2 GDP Outpaces; Facebook Hits User Activity Milestone
- Buffett's Berkshire Hathaway Discloses ~$4.5B Stake in Phillips 66 (PSX)
- Wall Street ends flat in quiet end to dramatic week
- Carl Icahn files 13D on Freeport-McMoran (FCX)
- Autodesk (ADSK) Tops Q2 EPS by 2c; Issues Light Q3 Outlook
As previously reported, on September 25, 2012, NuPathe Inc. (Nasdaq: PATH) entered into a Securities Purchase Agreement with certain qualified institutional purchasers and individual investors pursuant to which the Company agreed to sell to the Investors units of the Company’s securities for an aggregate purchase price of $28 million. The closing of the Proposed Financing is subject to certain specified closing conditions. In connection with the Proposed Financing, the Company is undertaking certain cost containment measures in order to focus its expenditures on gaining FDA approval of NP101, securing commercial partners and select pre-launch activities. The cost containment measures include, among others:
- A 50% reduction in workforce;
- Reducing expenditures relating to commercialization activities for NP101 and the earlier stage product candidates;
- Delaying the filing of an Investigational New Drug application for NP202, the Company’s product candidate for the long-term treatment of schizophrenia and bipolar disorder, until a co-development partner is obtained; and
- The previously reported restructuring of the Company’s outstanding debt under its term loan facility.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yingli Green Energy (YGE) Announces Prelim. Q2 GM at 6% - 7%; Notes Decline in Avg. PV Module Price
- Destination XL Group (DXLG) Tops Q2 EPS by 4c, Affirms FY Guiance
- GameStop (GME) Tops Q2 EPS by 7c; Boosts FY15 EPS Outlook
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings, Guidance
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!